(Q81604961)
English
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib
scientific article published on 01 April 2005
Statements
The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients (English)
Jan H M Schellens
Pauline Breedveld
Dick Pluim
Greta Cipriani
Peter Wielinga
Olaf van Tellingen
Alfred H Schinkel